Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Gabriel Leung Biography and Net Worth

Director of NovoCure

Gabriel Leung has been Vice Chairman and a director of Novocure since 2011. Mr. Leung retired as Executive Vice President of OSI Pharmaceuticals, Inc. and as the President of OSI’s Oncology and Diabetes Business following OSI’s acquisition by Astellas Pharma Inc. in 2010. Mr. Leung was responsible for the launch of Tarceva (erlotinib) at OSI Pharmaceuticals, guiding the product to the most successful launch in U.S. oncology history with global sales exceeding $1.2 billion in 2009. Prior to his tenure at OSI, Mr. Leung served as Group Vice President of the Global Prescription Business at Pharmacia Corporation from 1999 to 2003, leading Pharmacia’s oncology franchise with business and medical affairs operations in over 80 countries. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company. Mr. Leung previously served on the boards of Albany Molecular Research Inc., Delcath Systems, Inc. and Pernix Therapeutics Holdings, Inc. Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. Mr. Leung earned his M.S. in Pharmacy from the University of Wisconsin-Madison, with a concentration in pharmaceutical marketing.

What is Gabriel Leung's net worth?: The estimated net worth of Gabriel Leung is at least $2.27 million as of July 6th, 2021. Mr. Leung owns 73,859 shares of NovoCure stock worth more than $2,274,857 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Leung may own. Learn More about Gabriel Leung's net worth.
How do I contact Gabriel Leung?: The corporate mailing address for Mr. Leung and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Gabriel Leung's contact information.
Has Gabriel Leung been buying or selling shares of NovoCure?: Gabriel Leung has not been actively trading shares of NovoCure over the course of the past ninety days. Most recently, Gabriel Leung sold 1,000 shares of the business's stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $183.54, for a transaction totalling $183,540.00. Following the completion of the sale, the director now directly owns 73,859 shares of the company's stock, valued at $13,556,080.86. Learn More on Gabriel Leung's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Gabriel Leung Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2021	Sell	1,000	$183.54	$183,540.00	73,859
6/7/2021	Sell	1,000	$204.55	$204,550.00	73,045
5/5/2021	Sell	1,000	$199.67	$199,670.00	73,045
4/13/2021	Sell	6,000	$198.84	$1,193,040.00	78,045
9/14/2020	Sell	10,000	$95.00	$950,000.00	82,045
9/10/2020	Sell	10,000	$90.00	$900,000.00	81,159
9/2/2020	Sell	100	$85.00	$8,500.00	72,145
8/25/2020	Sell	7,112	$80.13	$569,884.56	79,157
7/30/2020	Sell	7,112	$75.00	$533,400.00	79,157
7/22/2020	Sell	9,500	$67.03	$636,785.00	72,545
11/25/2019	Sell	20,000	$95.00	$1,900,000.00	89,504
11/20/2019	Sell	20,000	$90.00	$1,800,000.00	89,504
11/18/2019	Sell	20,000	$90.68	$1,813,600.00
11/11/2019	Sell	5,000	$79.57	$397,850.00	74,504
10/10/2019	Sell	5,000	$72.28	$361,400.00	74,504
9/10/2019	Sell	5,000	$76.63	$383,150.00	74,504
8/12/2019	Sell	5,000	$86.45	$432,250.00	74,504
7/10/2019	Sell	5,000	$64.83	$324,150.00	74,504
6/19/2019	Sell	25,000	$60.02	$1,500,500.00	94,504
6/10/2019	Sell	5,000	$55.05	$275,250.00	74,504
5/10/2019	Sell	5,000	$49.79	$248,950.00
4/10/2019	Sell	5,000	$45.95	$229,750.00	65,000
3/11/2019	Sell	5,000	$48.31	$241,550.00	65,000
3/1/2019	Sell	25,000	$55.01	$1,375,250.00
2/11/2019	Sell	5,000	$49.59	$247,950.00	65,000
1/25/2019	Sell	20,000	$50.00	$1,000,000.00	80,000
1/16/2019	Sell	20,000	$45.00	$900,000.00	80,000
1/9/2019	Sell	20,000	$40.00	$800,000.00	80,000
12/10/2018	Sell	5,000	$33.49	$167,450.00	65,000
5/16/2018	Sell	80,000	$28.83	$2,306,400.00

Gabriel Leung Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $30.80

$30.33

$31.52

50 Day Range

MA: $21.12

$15.18

$33.41

2 Week Range

Now: $30.80

$11.70

$34.13

Volume

1,820,699 shs

Average Volume

1,336,846 shs

Market Capitalization

$3.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.